We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Bayer Aktiengesellschaft is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 4.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, BAYRY has gained about 12.3% so far this year. Meanwhile, the Medical sector has returned an average of -8.4% on a year-to-date basis. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Lonza Group Ag (LZAGY - Free Report) . The stock has returned 1.4% year-to-date.
For Lonza Group Ag, the consensus EPS estimate for the current year has increased 2.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 11 individual stocks and currently sits at #53 in the Zacks Industry Rank. Stocks in this group have lost about 8.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns.
On the other hand, Lonza Group Ag belongs to the Medical - Products industry. This 81-stock industry is currently ranked #168. The industry has moved -3.6% year to date.
Investors with an interest in Medical stocks should continue to track Bayer Aktiengesellschaft and Lonza Group Ag. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Bayer (BAYRY) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Bayer Aktiengesellschaft (BAYRY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Bayer Aktiengesellschaft is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Bayer Aktiengesellschaft is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 4.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, BAYRY has gained about 12.3% so far this year. Meanwhile, the Medical sector has returned an average of -8.4% on a year-to-date basis. This means that Bayer Aktiengesellschaft is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Lonza Group Ag (LZAGY - Free Report) . The stock has returned 1.4% year-to-date.
For Lonza Group Ag, the consensus EPS estimate for the current year has increased 2.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bayer Aktiengesellschaft belongs to the Large Cap Pharmaceuticals industry, which includes 11 individual stocks and currently sits at #53 in the Zacks Industry Rank. Stocks in this group have lost about 8.3% so far this year, so BAYRY is performing better this group in terms of year-to-date returns.
On the other hand, Lonza Group Ag belongs to the Medical - Products industry. This 81-stock industry is currently ranked #168. The industry has moved -3.6% year to date.
Investors with an interest in Medical stocks should continue to track Bayer Aktiengesellschaft and Lonza Group Ag. These stocks will be looking to continue their solid performance.